BioPharmSignal logoBioPharmSignal

Biotech News

TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants

TELA Bio (TELA)TELA BioFinancing

MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten registered direct offering of 4,189,000 shares of its common

Related news

TELATELA Bio2026-08-04 11:00 EST

TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director

TELATELA Bio2026-04-30 20:43 EST

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

View all latest news

TELA Bio

Soft-Tissue Reconstruction Company TELA Bio develops medical devices for hernia repair, abdominal-wall reconstruction, and plastic and reconstructive surgery. Reinforced Tissue Matrices The OviTex portfolio combines biologic tissue with polymer reinforcement to provide strength while supporting tissue remodeling. Commercial Surgical...

Recent company news

TELATELA Bio2026-08-10 20:05 EST

TELA Bio Reports Second Quarter 2026 Financial Results

TELATELA Bio2026-08-05 20:05 EST

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TELATELA Bio2026-08-04 11:00 EST

TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director

TELATELA Bio2026-07-29 20:05 EST

TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

TELATELA Bio2026-07-20 20:05 EST

TELA Bio to Announce Second Quarter 2026 Financial Results

Stock data

Close
0.65 USD
Market cap
40.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States